{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 77,
  "pageCount": 415,
  "prevPage": 76,
  "nextPage": 78,
  "slideType": "nominee_bio",
  "function": "introduce_nominees",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide serves as a negative testimonial/expert critique of the product.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/77",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-77",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Indicated lack of interest in Vykat at a recent, internal Journal Club meeting to review the phase 3 paper with “20 doctors that were in the room” – “people are a little hesitant when they hear the cost of it.”",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b29b-dfa0d2e465b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.86,
        "x": 0.07,
        "y": 0.69
      },
      "kind": "list",
      "text": "Indicated “we’re definitely cautious about it” because of diazoxide’s known risks for edema and cardiac failure; stated that his and colleagues’ interest in trialing a patient or two is flimsy at best; and expressed shock when we indicated the drug’s price, of which he was ignorant – “when we write for diazoxide, we always write for a diuretic at the same time, because we’ve seen heart failure on this drug a whole bunch of times”; “I don’t think people care unless it’s an absolute...that Prader-Willi drug sort of like came up. We’ll have a discussion about it. And, of course, we’ll have to learn more; “say that slowly again, the cost...oh my God.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "404df19f-fef9-465d-b52d-41260d189942",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.45
      },
      "kind": "list",
      "text": "Thinks that there may a small, initial bolus of physicians who trial any newly-approved drug “but I don’t think it will last that long” – “you get someone on it and you don’t notice the big difference, and it costs so much. I feel like people will eventually stop it.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9aa609da-d7f1-40e5-a074-f4d977778026",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.86,
        "x": 0.07,
        "y": 0.55
      },
      "kind": "list",
      "text": "Noticed no discussion or interest around Vykat at the recent annual Pediatric Endocrine Society meeting, the most important gathering of the year – “this is our big one...we have 1500 pediatric endocrinologists in the country and had 1100 people there...this was their big moment...I had no discussion to notice any vibe. Put it this way, no one talked about it and said wow, we’re really excited for this new indication. No one did that”; “this really hasn’t been a major topic.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6f2d3a3-aaef-48f6-bdab-dba5fc116295",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.86,
        "x": 0.07,
        "y": 0.24
      },
      "kind": "list",
      "text": "Indicated lack of interest in Vykat at a recent, internal Journal Club meeting to review the phase 3 paper with “20 doctors that were in the room” – “people are a little hesitant when they hear the cost of it.” The physician indicated that his CHOP colleagues haven’t even bothered to learn about Vykat; that he doesn’t think they’ve put a single patient on it; that he may consider trialing a patient at some point, but that he has heard of no interest in the drug from Prader-Willi families – “Muted. I’ve not had anyone call up at all. There’s been no push to do this drug. I have not had families call up at all.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee1882b2-e537-4a9f-a5cd-10e02bf50189",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“when we write for diazoxide, we always write for a diuretic at the same time, because we've seen heart failure on this drug a whole bunch of times” — PWS endocrinologist #2",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b29b-e3e44f3fe432",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a16e71b-6b53-49af-897e-cf64e92820e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "PWS endocrinologist #2: At Children’s Hospital of Philadelphia (CHOP), the top pediatric endocrinology program in the US and leading center for usage of diazoxide suspension for infant hyperinsulinism; previously held a key role at the Pediatric Endocrine Society, the key medical association for Soleno’s target market. Personally manages 4 PWS patients currently.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fe7c996-4cf1-4a08-851c-fffbc83377a9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}